Central Nervous System Drugs Global Market Report 2018

Central Nervous System Drugs Global Market Report 2018
Starting Price : $ 4000.00 | Pages : 125 | Published : February 2018

SKU CODE : 3258 | Format :

The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities. Top selling neurological drugs in 2017 include Copaxone, Lyrica, and Tecfidera.

North America was the largest region in the central nervous system drugs market in 2017, accounting for 37% market share. This can be attributed to high per capita spending on drugs to treat central nervous system disorders, the aging population and the insurance system which supports high healthcare costs in the USA. Western Europe was the second largest region accounting for 20% market share. Africa was the smallest region accounting for 4% market share.

Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for  research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2017, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.

Pharmaceutical Drugs Global Market Report 2018

Pharmaceutical Drugs Global Market Report 2018

Contract Research Organizations Global Market Report 2018

Pharmaceutical Drugs Global Market Report 2018

Contract Research Organizations Global Market Report 2018

Biologics Global Market Report 2018

Minor Orthopedic Replacement Implants Global Market Report 2018

Minor Orthopedic Replacement Implants Global Market Report 2018

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Organ-On-Chip Global Market 2018

View Report

Bio-Pharmaceutical Logistics Global Market Report 2018

View Report

Bio-Pharmaceutical Logistics Global Market Report 2018

View Report

Bio-Pharmaceutical Logistics Global Market Report 2018

View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)